Novo Nordisk cuts full-year forecasts due to slowing sales growth of obesity drugs, facing tough competition from Eli Lilly and copycat drugs. New CEO struggling to win over investors after weak quarter. Novo’s turnaround plan aims to regain market share, despite challenges from competitors and compounders. Novo also in takeover battle with Pfizer for biotech firm Metsera.

Unlawful mass compounding of GLP-1 drugs expands, impacting Novo’s sales. Wegovy sales slow amid competition, despite expectations of recovery. Lawsuits filed against pharmacies selling Wegovy copies. Medicare pricing deal under U.S. Inflation Reduction Act reached, easing uncertainty for investors. Novo and Lilly expected to cut prices of weight-loss drugs under separate deals with Trump administration.

Novo lowers full-year profit and sales growth forecasts. Operating profit expected to grow 4%-7%, down from 4%-10%. Sales growth projected at 8%-11%, decreased from 8%-14%. Slowest sales growth since early 2022 in third quarter. Shareholders express disappointment but support ongoing transformation process. Patience, focus, and disciplined execution key for company’s success.

Read more at Yahoo Finance: Novo Nordisk trims outlook as obesity drug maker loses ground to Eli Lilly